Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer

• Matti Kankainen,
• Timo Joensuu,
• Akseli Hemminki,
• Juuso Juhila,
• Siri Tähtinen,
• Otto Hemminki,
• Anna Kanerva,
• Kristian Taipale,
• Ilkka Liikanen,
• Minna Oksanen,
• Dafne C A Quixabeira,
• Saru Basnet

Affiliations

Matti Kankainen

Aff1 grid.452494.a0000000404095350Institute for Molecular Medicine Finland Helsinki Finland

Timo Joensuu

Aff4 Docrates Cancer Center Helsinki Finland

Akseli Hemminki

Cancer Gene Therapy Group, Helsingin yliopisto, Helsinki, Uusimaa, Finland

Juuso Juhila

Aff2 grid.430088.7Oncos Therapeutics Helsinki Finland

Siri Tähtinen

Aff29 grid.7737.40000000404102071University of Helsinki Helsinki Uusimaa Finland

Otto Hemminki

Aff377 grid.7737.40000000404102071University of Helsinki Helsinki Uusimaa Finland

Anna Kanerva

Aff377 grid.7737.40000000404102071University of Helsinki Helsinki Uusimaa Finland

Kristian Taipale

Aff1 grid.7737.40000000404102071Cancer Gene Therapy GroupUniversity of Helsinki Helsinki Finland

Ilkka Liikanen

Aff1 grid.7737.40000000404102071Cancer Gene Therapy GroupUniversity of Helsinki Helsinki Finland

Minna Oksanen

Aff1 grid.7737.40000000404102071Cancer Gene Therapy GroupUniversity of Helsinki Helsinki Finland

Dafne C A Quixabeira

Translational Immunology Research Program, Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland

Saru Basnet

Translational Immunology Research Program, Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland